<DOC>
	<DOCNO>NCT00005856</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose oxaliplatin treating patient newly diagnose glioblastoma multiforme . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oxaliplatin patient newly diagnose glioblastoma multiforme receive receive anticonvulsant know metabolized P450 . II . Determine dose-limiting toxicity safety profile drug patient population . III . Assess pharmacokinetics drug schedule determine effect P450-inducing anticonvulsant pharmacokinetics patient . IV . Determine radiographic response rate patient treat drug . V. Determine survival drug toxicity patient . OUTLINE : This phase I dose-escalation study oxaliplatin follow phase II study . Patients stratify accord whether concurrent anticonvulsant drug induce P450 ( yes v modest/no drug ) . Phase I : Patients receive oxaliplatin IV 2 hour day 1 . Treatment repeat every 14 day maximum 6 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient ( per stratum ) receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive oxaliplatin phase I MTD determine phase I . Patients follow 1 month , every 2 month disease progression , monthly thereafter . PROJECTED ACCRUAL : Approximately 24 patient ( 12 per stratum ) accrue phase I part study within 8-12 month . A total 18-35 patient accrue phase II part study within 5-12 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm supratentorial grade IV astrocytoma Glioblastoma multiforme Subtotal resection biopsy measurable contrastenhancing disease postoperative , pretreatment MRI/CT scan Performance status Karnofsky 60100 % Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin normal Creatinine normal Creatinine clearance least 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection medical illness would jeopardize ability receive protocol chemotherapy reasonable safety No prior malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer No grade 2 great preexist sensory neuropathy No history allergy platinum compound antiemetic appropriate administration conjunction protocol chemotherapy Mini mental score least 15 No prior immunotherapy glioblastoma multiforme No prior biologic therapy glioblastoma multiforme , include : Immunotoxins Immunoconjugates Antiangiogenesis compound Antisense Peptide receptor antagonist Interferons Interleukins Tumor infiltrate lymphocyte Lymphokine activate killer cell Gene therapy No concurrent filgrastim ( GCSF ) No prior chemotherapy glioblastoma multiforme No prior hormonal therapy glioblastoma multiforme Prior glucocorticoid therapy glioblastoma multiforme allow Must maintain stable ( low require dose ) corticosteroid regimen least 5 day study No concurrent dexamethasone antiemetic No prior radiotherapy glioblastoma multiforme Recovered immediate postoperative period At least 10 day since prior anticonvulsant drug induces hepatic metabolic enzymes No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>